checkAd
    MoonLake Immunotherapeutics Registered (A) Aktie
    41,08
     
    USD
    -1,49 %
    -0,62 USD
    Letzter Kurs 29.05.24 NMS
    41,08
     
    USD
    200 STK
    Geldkurs 29.05.24
    41,16
     
    USD
    300 STK
    Briefkurs 29.05.24
    ISIN: KY61559X1045 · WKN: A3DFA7 · SYM: MLTX · Kaiman-Inseln

    Neueste Nachrichten

    MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
    16.05.24 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
    07.05.24 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions 
    10.04.24 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
    10.03.24 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
    04.03.24 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
    29.02.24 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
    26.02.24 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
    14.11.23 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis
    05.11.23 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
    15.10.23 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
    11.10.23 · globenewswire · MoonLake Immunotherapeutics Registered (A)
    Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
    04.10.23 · globenewswire · MoonLake Immunotherapeutics Registered (A)